Why are so many people still being arrested for marijuana across Pennsylvania?

“We’re still arresting more people than we did 10 years ago,” said Lt. Gov. John Fetterman. “It’s lunacy.”

Why are so many people still being arrested for marijuana across Pennsylvania?

“We’re still arresting more people than we did 10 years ago,” said Lt. Gov. John Fetterman. “It’s lunacy.”

Glaxo, Merck to spin off some businesses to focus on high-profit cancer drugs and vaccines

Drug giants Glaxo and Merck, which have research, manufacturing and marketing operations in the Philadelphia area, plan to spin off slow-growing businesses to concentrate on high-profit therapies

Glaxo, Merck to spin off some businesses to focus on high-profit cancer drugs and vaccines

Drug giants Glaxo and Merck, which have research, manufacturing and marketing operations in the Philadelphia area, plan to spin off slow-growing businesses to concentrate on high-profit therapies

Penn gene therapy pioneer Jim Wilson’s Passage Bio plans IPO

Penn gene therapy pioneer Jim Wilson's Passage Bio is planning to go public.

Penn gene therapy pioneer Jim Wilson’s Passage Bio plans IPO

Penn gene therapy pioneer Jim Wilson's Passage Bio is planning to go public.
More Stories

Annovis Bio is the latest Philly-area biotech firm to sell stock before it has products

Annovis is developing an anti-Alzheimer’s treatment that the company says could also be useful fighting Parkinson’s and other neurodegenerative diseases.

Delaware gets approval from USDA to grow hemp. Is that a good thing?

One industry analyst warns that aspiring hemp farmers in any state take caution.

‘Skunkworks’ at Johnson & Johnson is rushing to develop a coronavirus vaccine

J&J set up the project two weeks ago when the virus began to look like a global threat.

Pa. auditor general presses for new laws on pharmacy benefit managers

Auditor general Eugene DePasquale said Thursday said that pharmacy benefit manager business practices are “harming” independent pharmacies, and that he was concerned about the “future of competition” among retail pharmacies in the state.

Philly-area company gets $9 million grant to develop vaccine for new Chinese coronavirus

The company hopes to begin human testing of a vaccine within months.

Remember that $8 billion Risperdal verdict? A Philly judge has drastically slashed it

A Philadelphia county judge slashed the shocking verdict against Janssen Pharmaceuticals to $6.8 million.

N.J. company must pay for employee’s medical marijuana, appeals court rules

“This is huge. And the significance of this court decision cannot be overstated,” said one cannabis attorney.

FDA approves Philadelphia company’s cocaine drug

Numbrino will be marketed for in-office diagnostic procedures and minor in-office surgery.

RNA: Philly drug developer Aro to get $1.4 billion if it meets Ionis’ targets

U City start-up Aro Biotherapeutics sets targets to deliver RNA drugs

Reading the tea leaves: What 10 cannabis bigwigs predict 2020 will bring to the world of weed

In Pennsylvania, you’ll see more supply coming to the market in 2020. Meanwhile a referendum in New Jersey could accelerate the push to legalization.

Genetic test at Acme pharmacies guides choice of psychiatric medications

The test, which is evaluated by a King of Prussia company and requires a prescription, is available at all 37 ACME pharmacies in southeastern Pennsylvania,

THC vape dealers are stealing customers’ money online, FDA says

If you must vape, buy from a state-regulated dispensary.

Column

Cell Factory Town: Philly docs expect Roche-Spark deal will draw billions ($$$) and thousands (jobs) to new gene labs here

Roche's " vision is very much, long-term oriented, to make Philadelphia the center of excellence for gene therapy within the Roche group” under the Spark name, said Spark CEO Jeffrey Marrazzo

SPECIAL REPORTS
Investigative reports, featured series, and guides to living in the Philadelphia region, brought to you by The Inquirer.
WHAT ARE YOU CURIOUS ABOUT?
Send us your burning questions, or vote on other readers' questions that pique your interest. Our journalists will work to answer them.